USDA Agricultural Marketing Service. Creating opportunities for farmers and businesses. Image: Aerial view of red barn on green terrain.

Seed Sower: Pending Patents Published June 27, 2024

USDA Agricultural Marketing Service sent this bulletin at 07/03/2024 11:56 AM EDT

Trouble viewing this email? View it as a webpage.

SEED SOWER

Pending Patents Published June 27, 2024

Welcome to the weekly edition of Seed Sower, which shares a list of pending patents published the previous week by the U.S. Patent and Trademark Office. These patent applications cover seed-bearing plants and non-transgenic plant breeding methods only.

The USDA Seed Liaison helps those who work with seeds to navigate a complex system by increasing transparency about intellectual property related to seeds, among other things. Learn more about the Seed Liaison initiative.

INTROGRESSION OF TOLCNDV-ES RESISTANCE CONFERRING QTLS IN CUCUMIS SATIVUS PLANTS

PLANT HAVING ENHANCED RESISTANCE AGAINST COLORADO POTATO BEETLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR EVALUATING RESISTANCE AGAINST COLORADO POTATO BEETLE IN PLANT

LETTUCE VARIETY NUN 06340 LTL

HYBRID TOMATO VARIETY 'H2247'

HYBRID TOMATO VARIETY 'H2355'

HYBRID TOMATO VARIETY 'H2239'

HYBRID TOMATO VARIETY 'H2354'

HYBRID TOMATO VARIETY 'H2249'

AGAPANTHUS PLANT NAMED 'MONSAPHO'

LEWISIA PLANT NAMED 'LOCORA3519'

This list includes the titles of all U.S. patent applications published on June 27, 2024 with the following Cooperative Plant Classification:

A01H: New plants or {non-transgenic} processes for obtaining them; plant reproduction by tissue culture techniques | 6: Angiosperms, i.e. Flowering plants, characterised by their botanic taxonomy

Patents can have more than one classification. There may be other classifications of interest to plant breeders. View all classifications for A01H.

To assist the reader in understanding each patent application, each title below is followed by the application's abstract and its independent claims.

The abstract is a short summary of the invention that allows the reader to understand the gist of disclosed invention. Independent (standalone) claims define the scope of the patent protection being sought. Independent claims may also be followed by one or more dependent claims, which are not listed here in the interest of brevity. A number of patents from the same applicant with similar abstracts, titles, and claims are listed along with a representative example of the abstract and independent claims in each patent.

To see the application’s complete list of claims:

Click the patent title to open the application in Patent Center.
Click “Download PDF.”
Find the numbered list of claims, usually located at the end of the document.

Some applications are excluded from Pre-Grant Publication. Those applications include: applications recognized by the Office as no longer pending; applications that are national security classified (see 37 CFR 5.2(c)), subject to a secrecy order under 35 U.S.C. 181, or under national security review; applications that have been issued as a patent in sufficient time to be removed from the publication process; and applications filed with a nonpublication request in compliance with 37 CFR 1.213(a). See MPEP § 1122-1124.

Members of the public have the option of filing third party submissions of prior art to pending patent applications. Prior art may be any evidence that what is claimed in the patent application has already been publicly described. Learn more about third party preissuance submissions.

The Seed Liaison welcomes your feedback, questions, and concerns at seedliaison@usda.gov.

INTROGRESSION OF TOLCNDV-ES RESISTANCE CONFERRING QTLS IN CUCUMIS SATIVUS PLANTS

Applicants: NUNHEMS B.V.

Abstract: The present invention relates to cultivated cucumber plants comprising one or more QTLs on chromosome 1, 2 and/or 3 of their genome conferring enhanced ToLCNDV-ES resistance, and to methods for generating such plants, and their use.

Independent Claims:

1. A cultivated Cucumis sativus sativus plant comprising at least two introgression fragments on chromosome 1, 2 and/or 3 from a wild cucumber donor wherein one of said fragments comprises QTL1.1, or said plant comprises at least three introgression fragments on chromosome 1, 2 and/or 3, wherein each of said introgression fragments comprises a Quantitative Trait Locus (QTL) selected from the QTLs designated QTL1.1, QTL1.2, QTL2.1 and QTL3.1, wherein QTL1.1 is located on chromosome 1 between the Single Nucleotide Polymorphism marker SNP_01 at nucleotide 51 of SEQ ID NO: 1 and SNP_16 at nucleotide 51 of SEQ ID NO: 16, QTL1.2 is located on chromosome 1 between SNP_17 at nucleotide 51 of SEQ ID NO: 17 and SNP_31 at nucleotide 51 of SEQ ID NO: 31, QTL2.1 is located on chromosome 2 between SNP_32 at nucleotide 51 of SEQ ID NO: 32 and SNP_47 at nucleotide 51 of SEQ ID NO: 47, and QTL3.1 is located on chromosome 3 between SNP_48 at nucleotide 51 of SEQ ID NO: 48 and SNP_62 at nucleotide 51 of SEQ ID NO: 62, which QTLs confer an increase in Tomato Leaf Curl New Delhi Virus strain ToLCNDV-ES and wherein said introgression fragment on chromosome 1 comprising QTL1.1 comprises a SNP haplotype or SNP genotype of at least 5, preferably-at-last markers selected from the group consisting of: a) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_01 at nucleotide 51 of SEQ ID NO: 1 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 1; b) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_02 at nucleotide 51 of SEQ ID NO: 2 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 2; c) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_03 at nucleotide 51 of SEQ ID NO: 3 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 3; d) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_04 at nucleotide 51 of SEQ ID NO: 4 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 4; e) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_05 at nucleotide 51 of SEQ ID NO: 5 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 5; f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_06 at nucleotide 51 of SEQ ID NO: 6 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 6; g) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_07 at nucleotide 51 of SEQ ID NO: 7 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 7; h) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_08 at nucleotide 51 of SEQ ID NO: 8 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 8; i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_09 at nucleotide 51 of SEQ ID NO: 9 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 9; or the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_09 at nucleotide 51 of SEQ ID NO: 9 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 9; j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_10 at nucleotide 51 of SEQ ID NO: 10 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 10; k) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_11 at nucleotide 51 of SEQ ID NO: 11 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 11; l) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_12 at nucleotide 51 of SEQ ID NO: 12 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 12; m) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_13 at nucleotide 51 of SEQ ID NO: 13 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 13; n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_14 at nucleotide 51 of SEQ ID NO: 14 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 14; o) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_15 at nucleotide 51 of SEQ ID NO: 15 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 15; or the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_15 at nucleotide 51 of SEQ ID NO: 15 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 15; and p) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_16 at nucleotide 51 of SEQ ID NO: 16 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 16; wherein said introgression fragment on chromosome 1 comprising QTL1.2 comprises a SNP haplotype or SNP genotype of at least 5, markers selected from the group consisting of: a) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_17 at nucleotide 51 of SEQ ID NO: 17 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 17; b) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_18 at nucleotide 51 of SEQ ID NO: 18 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 18; c) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_19 at nucleotide 51 of SEQ ID NO: 19 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 19; d) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_20 at nucleotide 51 of SEQ ID NO: 20 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 20; e) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_21 at nucleotide 51 of SEQ ID NO: 21 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 21; f) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_22 at nucleotide 51 of SEQ ID NO: 22 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 22; g) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_23 at nucleotide 51 of SEQ ID NO: 23 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 23; h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_24 at nucleotide 51 of SEQ ID NO: 24 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 24; i) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_25 at nucleotide 51 of SEQ ID NO: 25 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 25; j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_26 at nucleotide 51 of SEQ ID NO: 26 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 26; k) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_27 at nucleotide 51 of SEQ ID NO: 27 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 27; l) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_28 at nucleotide 51 of SEQ ID NO: 28 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 28; m) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_29 at nucleotide 51 of SEQ ID NO: 29 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 29; n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_30 at nucleotide 51 of SEQ ID NO: 30 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 30; and o) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_31 at nucleotide 51 of SEQ ID NO: 31 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 31; wherein said introgression fragment on chromosome 2 comprising QTL2.1 comprises a SNP haplotype or SNP genotype of at least 5 markers selected from the group consisting of: a) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_32 at nucleotide 51 of SEQ ID NO: 32 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 32; b) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_33 at nucleotide 51 of SEQ ID NO: 33 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 33; c) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_34 at nucleotide 51 of SEQ ID NO: 34 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 34; d) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_35 at nucleotide 51 of SEQ ID NO: 35 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 35; e) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_36 at nucleotide 51 of SEQ ID NO: 36 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 36; f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_37 at nucleotide 51 of SEQ ID NO: 37 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 37; g) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_38 at nucleotide 51 of SEQ ID NO: 38 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 38; h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_39 at nucleotide 51 of SEQ ID NO: 39 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 39; i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_40 at nucleotide 51 of SEQ ID NO: 40 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 40; j) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_41 at nucleotide 51 of SEQ ID NO: 41 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 41; k) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_42 at nucleotide 51 of SEQ ID NO: 42 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 42; l) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_43 at nucleotide 51 of SEQ ID NO: 43 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 43; m) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_44 at nucleotide 51 of SEQ ID NO: 44 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 44; n) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_45 at nucleotide 51 of SEQ ID NO: 45 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 45; o) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_46 at nucleotide 51 of SEQ ID NO: 46 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 46; and p) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_47 at nucleotide 51 of SEQ ID NO: 47 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 47; wherein said introgression fragment on chromosome 3 comprising QTL3.1 comprises a SNP haplotype or SNP genotype of at least 5 markers selected from the group consisting of: a) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_48 at nucleotide 51 of SEQ ID NO: 48 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 48; b) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_49 at nucleotide 51 of SEQ ID NO: 49 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 49; c) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_50 at nucleotide 51 of SEQ ID NO: 50 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 50; d) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_51 at nucleotide 51 of SEQ ID NO: 51 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 51; e) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_52 at nucleotide 51 of SEQ ID NO: 52 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 52; f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_53 at nucleotide 51 of SEQ ID NO: 53 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 53; g) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_54 at nucleotide 51 of SEQ ID NO: 54 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 54; h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_55 at nucleotide 51 of SEQ ID NO: 55 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 55; i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_56 at nucleotide 51 of SEQ ID NO: 56 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 56; j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_57 at nucleotide 51 of SEQ ID NO: 57 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 57; k) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_58 at nucleotide 51 of SEQ ID NO: 58 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 58; l) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_59 at nucleotide 51 of SEQ ID NO: 59 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 59; m) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_60 at nucleotide 51 of SEQ ID NO: 60 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 60; n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_61 at nucleotide 51 of SEQ ID NO: 61 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 61; and o) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_62 at nucleotide 51 of SEQ ID NO: 62 or at the equivalent position in a sequence comprising at least 95% sequence identity to SEQ ID NO: 62.

11. A method for identifying a wild cucumber comprising a ToLCNDV-ES resistance QTL on chromosome 1, 2 and/or 3, said method comprising: a) providing a wild or primitive cucumber accession or several accessions; b) screening said accession(s) using a molecular marker assay which detects at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more of the SNP markers linked to at least one QTL selected from QTL1.1, QTL1.2, QTL2.1 and/or QTL3.1; and c) identifying and/or selecting an accession from b) comprising the SNP haplotype or SNP genotype of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 of the SNP markers linked to a QTL, selected from: for QTL1.1: a) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_01 at nucleotide 51 of SEQ ID NO: 1 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 1); b) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_02 at nucleotide 51 of SEQ ID NO: 2 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 2); c) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_03 at nucleotide 51 of SEQ ID NO: 3 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 3); d) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_04 at nucleotide 51 of SEQ ID NO: 4 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 4); e) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_05 at nucleotide 51 of SEQ ID NO: 5 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 5); f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_06 at nucleotide 51 of SEQ ID NO: 6 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 6); g) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_07 at nucleotide 51 of SEQ ID NO: 7 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 7); h) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_08 at nucleotide 51 of SEQ ID NO: 8 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 8); i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_09 at nucleotide 51 of SEQ ID NO: 9 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 9); or the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_09 at nucleotide 51 of SEQ ID NO: 9 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 9); j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_10 at nucleotide 51 of SEQ ID NO: 10 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 10); k) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_11 at nucleotide 51 of SEQ ID NO: 11 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 11); l) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_12 at nucleotide 51 of SEQ ID NO: 12 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 12); m) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_13 at nucleotide 51 of SEQ ID NO: 13 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 13); n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_14 at nucleotide 51 of SEQ ID NO: 14 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 14); o) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_15 at nucleotide 51 of SEQ ID NO: 15 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 15); or the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_15 at nucleotide 51 of SEQ ID NO: 15 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 15); p) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_16 at nucleotide 51 of SEQ ID NO: 16 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 16). for QTL1.2: a) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_17 at nucleotide 51 of SEQ ID NO: 17 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 17); b) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_18 at nucleotide 51 of SEQ ID NO: 18 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 18); c) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_19 at nucleotide 51 of SEQ ID NO: 19 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 19); d) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_20 at nucleotide 51 of SEQ ID NO: 20 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 20); e) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_21 at nucleotide 51 of SEQ ID NO: 21 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 21); f) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_22 at nucleotide 51 of SEQ ID NO: 22 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 22); g) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_23 at nucleotide 51 of SEQ ID NO: 23 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 23); h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_24 at nucleotide 51 of SEQ ID NO: 24 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 24); i) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_25 at nucleotide 51 of SEQ ID NO: 25 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 25); j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_26 at nucleotide 51 of SEQ ID NO: 26 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 26); k) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_27 at nucleotide 51 of SEQ ID NO: 27 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 27); l) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_28 at nucleotide 51 of SEQ ID NO: 28 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 28); m) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_29 at nucleotide 51 of SEQ ID NO: 29 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 29); n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_30 at nucleotide 51 of SEQ ID NO: 30 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 30); o) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_31 at nucleotide 51 of SEQ ID NO: 31 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 31). for QTL2.1: a) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_32 at nucleotide 51 of SEQ ID NO: 32 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 32); b) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_33 at nucleotide 51 of SEQ ID NO: 33 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 33); c) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_34 at nucleotide 51 of SEQ ID NO: 34 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 34); d) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_35 at nucleotide 51 of SEQ ID NO: 35 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 35); e) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_36 at nucleotide 51 of SEQ ID NO: 36 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 36); f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_37 at nucleotide 51 of SEQ ID NO: 37 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 37); g) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_38 at nucleotide 51 of SEQ ID NO: 38 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 38); h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_39 at nucleotide 51 of SEQ ID NO: 39 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 39); i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_40 at nucleotide 51 of SEQ ID NO: 40 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 40); j) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_41 at nucleotide 51 of SEQ ID NO: 41 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 41); k) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_42 at nucleotide 51 of SEQ ID NO: 42 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 42); l) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_43 at nucleotide 51 of SEQ ID NO: 43 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 43); m) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_44 at nucleotide 51 of SEQ ID NO: 44 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 44); n) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_45 at nucleotide 51 of SEQ ID NO: 45 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 45); o) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_46 at nucleotide 51 of SEQ ID NO: 46 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 46); p) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_47 at nucleotide 51 of SEQ ID NO: 47 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 47). for QTL3.1: a) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_48 at nucleotide 51 of SEQ ID NO: 48 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 48); b) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_49 at nucleotide 51 of SEQ ID NO: 49 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 49); c) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_50 at nucleotide 51 of SEQ ID NO: 50 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 50); d) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_51 at nucleotide 51 of SEQ ID NO: 51 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 51); e) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_52 at nucleotide 51 of SEQ ID NO: 52 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 52); f) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_53 at nucleotide 51 of SEQ ID NO: 53 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 53); g) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_54 at nucleotide 51 of SEQ ID NO: 54 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 54); h) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_55 at nucleotide 51 of SEQ ID NO: 55 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 55); i) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_56 at nucleotide 51 of SEQ ID NO: 56 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 56); j) the CX or CC genotype for the Single Nucleotide Polymorphism marker SNP_57 at nucleotide 51 of SEQ ID NO: 57 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 57); k) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_58 at nucleotide 51 of SEQ ID NO: 58 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 58); l) the TX or TT genotype for the Single Nucleotide Polymorphism marker SNP_59 at nucleotide 51 of SEQ ID NO: 59 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 59); m) the GX or GG genotype for the Single Nucleotide Polymorphism marker SNP_60 at nucleotide 51 of SEQ ID NO: 60 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 60); n) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_61 at nucleotide 51 of SEQ ID NO: 61 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 61); o) the AX or AA genotype for the Single Nucleotide Polymorphism marker SNP_62 at nucleotide 51 of SEQ ID NO: 62 (or at nucleotide 51 of a sequence comprising at least 95% sequence identity to SEQ ID NO: 62).

PLANT HAVING ENHANCED RESISTANCE AGAINST COLORADO POTATO BEETLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR EVALUATING RESISTANCE AGAINST COLORADO POTATO BEETLE IN PLANT

*Non Final Action Mailed*

Applicants: KANEKA CORPORATION; NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY; NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION; RIKEN

Abstract: The spirosolane skeleton 23-position hydroxylase gene and the spirosolane skeleton 23-position acetyltransferase gene derived from S. chacoense, S. tuberosum, and S. lycopersicum are found to be involved with the biosynthesis of leptine, which achieves resistance against Colorado potato beetle.

Independent Claims:

2. A composition comprising: at least one DNA selected from the group consisting of (d) to (f) below: (d) DNA encoding a protein that consists of an amino acid sequence as set forth in SEQ ID NO: 8, 10, or 12; (e) DNA encoding a protein that consists of an amino acid sequence having 80% or higher identity to an amino acid sequence as set forth in SEQ ID NO: 8, 10, or 12, and has an activity to acetylate a hydroxy group of position 23 of a spirosolane skeleton; and (f) DNA that hybridizes under stringent conditions with DNA consisting of a complementary sequence to a nucleotide sequence as set forth in SEQ ID NO: 7, 9, or 11, and encodes a protein having an activity to acetylate a hydroxy group of position 23 of a spirosolane skeleton.

LETTUCE VARIETY NUN 06340 LTL

Applicants: Nunhems B.V.

Abstract: A new and distinct lettuce variety NUN 06340 LTL is disclosed, as well as seeds and plants and heads or leaves thereof.

Independent Claims:

1. A plant or seed of lettuce variety NUN 06340 LTL, wherein a representative sample of seed of said lettuce variety NUN 06340 LTL has been deposited under Accession Number NCIMB 44176.

18. A method of producing a modified lettuce plant, said method comprising mutating a target gene by targeted gene editing in lettuce plant or plant part of lettuce variety NUN 06340 LTL, wherein a representative sample of seed of said lettuce variety NUN 06340 LTL has been deposited under Accession Number NCIMB 44176, and wherein the target gene modifies a desired trait and wherein the desired trait is male sterility, herbicide tolerance, insect resistance, pest resistance, disease resistance, environmental stress tolerance, modified carbohydrate metabolism, or modified protein metabolism.

HYBRID TOMATO VARIETY 'H2247'